Brain diffusion alterations in patients with COVID-19 pathology and neurological manifestations

被引:14
|
作者
Caroli, Anna [1 ]
Capelli, Serena [1 ]
Napolitano, Angela [2 ]
Cabrini, Giulia [3 ]
Arrigoni, Alberto [1 ]
Pezzetti, Giulio [2 ]
Previtali, Mattia [1 ]
Longhi, Luca Giovanni [4 ]
Zangari, Rosalia [5 ]
Lorini, Ferdinando Luca [6 ]
Sessa, Maria [7 ]
Remuzzi, Andrea [3 ]
Gerevini, Simonetta [2 ,8 ]
机构
[1] Ist Ric Farmacol Mario Negri IRCCS, Bioengn Dept, I-24020 Ranica, BG, Italy
[2] ASST Papa Giovanni XXIII, Dept Neuroradiol, I-24127 Bergamo, Italy
[3] Univ Bergamo, Dept Management Informat & Prod Engn, I-24044 Dalmine, BG, Italy
[4] ASST Papa Giovanni XXIII, Dept Anesthesia & Crit Care Med, Neurosurg Intens Care Unit, Bergamo, Italy
[5] ASST Papa Giovanni XXIII, FROM Res Fdn, I-24127 Bergamo, Italy
[6] ASST Papa Giovanni XXIII, Dept Emergency & Crit Care Area, Bergamo, Italy
[7] ASST Papa Giovanni XXIII, Dept Neurol, I-24127 Bergamo, Italy
[8] ASST Papa Giovanni XXIII, Dept Neuroradiol, Piazza OMS 1, I-24127 Bergamo, Italy
关键词
COVID-19; Diffusion weighted imaging; ADC; Neuroinflammation;
D O I
10.1016/j.nicl.2023.103338
中图分类号
R445 [影像诊断学];
学科分类号
100207 ;
摘要
Background and objective: COVID-19 neurological manifestations have been progressively recognized. Among available MRI techniques, diffusion weighted imaging (DWI) shows promise to study microstructure, inflammation, and edema. Previous DWI studies reported alterations in brain diffusivity in COVID-19 patients, as assessed by morphologic evaluation of brain DWI scans only. The aim of this study was to assess and quantify brain diffusion alterations in COVID-19 patients with neurological manifestations. Methods: 215 COVID-19 patients with neurological manifestations (olfactory and/or other neurological disorders) and 36 normal controls were compared and studied with DWI and T1-weighted MRI scans. MRI scans were processed by a semi-automatic processing procedure specifically developed for the purpose of this study, and the Apparent Diffusion Coefficient (ADC) was quantified in different brain tissues and individual white matter (WM) and gray matter (GM) regions. Differences in ADC values were assessed between COVID-19 patients and normal controls, as well as in the COVID-19 patient population grouped by hospitalization and neurological symptoms. Results: Among COVID-19 patients (median [IQR] = 52 [42 - 60] years of age, 58 % females), 91 were hospitalized and 26 needed intensive care. 84 patients had hyposmia/ageusia only, while 131 ones showed other neurological disorders. COVID-19 patients showed significantly increased ADC values in the WM and in several GM regions (p < 0.001). ADC values were significantly correlated with MRI time from disease onset (p < 0.05). Hospitalized patients showed significantly higher ADC alteration than non-hospitalized patients in all brain tissues; similarly, COVID-19 patients with neurological disorders showed significantly higher ADC values than those with olfactory loss only. ADC alteration was highest in patients with cognitive or memory disorder and in those with encephalitis or meningitis. ADC values were neither associated with the duration of hospitalization nor with the need for intensive care.Conclusion: Current findings suggest DWI potential as a non-invasive marker of neuroinflammation in COVID-19, and the transient nature of the same. Future longitudinal studies are needed to confirm our findings.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Neurological manifestations of COVID-19: a systematic review
    Nepal, Gaurav
    Rehrig, Jessica Holly
    Shrestha, Gentle Sunder
    Shing, Yow Ka
    Yadav, Jayant Kumar
    Ojha, Rajeev
    Pokhrel, Gaurab
    Tu, Zhi Lan
    Huang, Dong Ya
    [J]. CRITICAL CARE, 2020, 24 (01)
  • [42] A Systematic Review of Neurological Manifestations of COVID-19
    Magar, Sumeru Thapa
    Lokhandwala, Hatim I.
    Batool, Saima
    Zahoor, Faiqa
    Zaidi, Syeda Kisa Fatima
    Sahtiya, Saveeta
    Khemani, Deepa
    Kumar, Sumeet
    Voloshyna, Diana
    Saleem, Faraz
    Ghaffari, Muhammad Abu Zar
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)
  • [43] Lifting the mask on neurological manifestations of COVID-19
    Alessandro Pezzini
    Alessandro Padovani
    [J]. Nature Reviews Neurology, 2020, 16 : 636 - 644
  • [44] Lifting the mask on neurological manifestations of COVID-19
    Pezzini, Alessandro
    Padovani, Alessandro
    [J]. NATURE REVIEWS NEUROLOGY, 2020, 16 (11) : 636 - 644
  • [45] Neurological manifestations and implications of COVID-19 pandemic
    Tsivgoulis, Georgios
    Palaiodimou, Lina
    Katsanos, Aristeidis H.
    Caso, Valeria
    Koehrmann, Martin
    Molina, Carlos
    Cordonnier, Charlotte
    Fischer, Urs
    Kelly, Peter
    Sharma, Vijay K.
    Chan, Amanda C.
    Zand, Ramin
    Sarraj, Amrou
    Schellinger, Peter D.
    Voumvourakis, Konstantinos I.
    Grigoriadis, Nikolaos
    Alexandrov, Andrei V.
    Tsiodras, Sotirios
    [J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13
  • [46] Neurological manifestations of COVID-19, SARS and MERS
    Kato, Verstrepen
    Laure, Baisier
    Harald, De Cauwer
    [J]. ACTA NEUROLOGICA BELGICA, 2020, 120 (05) : 1051 - 1060
  • [47] Neurological manifestations of COVID-19-an approach to categories of pathology
    Leven, Yana
    Boesel, Julian
    [J]. NEUROLOGICAL RESEARCH AND PRACTICE, 2021, 3 (01):
  • [48] Neurological manifestations of COVID-19: A brief review
    Sachdev, Kirti
    Agrawal, Sumita
    Ish, Pranav
    Gupta, Nitesh
    Raheja, Kapil
    [J]. INDIAN JOURNAL OF MEDICAL RESEARCH, 2020, 152 (01) : 41 - 47
  • [49] Spectrum of Neurological Manifestations in Covid-19: A Review
    Garg, Ravindra K.
    [J]. NEUROLOGY INDIA, 2020, 68 (03) : 560 - 572
  • [50] Neurological manifestations and pathogenic mechanisms of COVID-19
    Galea, Matteo
    Agius, Michaela
    Vassallo, Neville
    [J]. NEUROLOGICAL RESEARCH, 2022, 44 (07) : 571 - 582